熱門資訊> 正文
随着美国销售额的增长，Haleon利用了GL-1的副作用
2026-09-16 23:43
- Haleon(HLN) 0
- 沃爾瑪(WMT) 0
- 禮來(LLY) 0
- Haleon has seen an uptick in US sales of some of its over-the-counter products, including the pain reliever Advil and the antacid Tums, as users of GLP-1 weight-loss medications turn to the products to deal with side effects.
- The consumer health company is even teaming up with stores including CVS (CVS) to have its products placed in areas frequented by weight-loss drugs patients.
- "Dual placement in core aisles and GLP-1 destination sets delivers an average 24% sales lift per store," a Haleon spokesperson told Reuters, adding that items placed on designated GLP-1 shelves are outselling the same ones in stores without them.
- The spokesperson added that the company has also been in discussions with Walmart (WMT) and Target (TGT).
- Eli Lilly (LLY) and Novo Nordisk (NVO) are the biggest manufacturers of prescription weight-loss therapies. Lilly markets Zepbound (tirzepatide) and Foundayo (orforglipron), an oral treatment, while Novo sells Wegovy (semaglutide) and a pill version of it.
More on Haleon
- Haleon: Decent Growth Prospects, But Still Not A Bargain
- Haleon plc (HLN) Q2 2026 Earnings Call Prepared Remarks Transcript
- Haleon plc 2026 Q2 - Results - Earnings Call Presentation
- Haleon plc Non-GAAP EPS of 10.30p, revenue of £5.6B; reaffirms FY outlook
- Haleon inks five-year partnership with Microsoft
推薦文章
華盛早報｜SK海力士Q3營業利潤飆7倍！擬回饋股東100萬億韓元；甲骨文加碼英偉達、谷歌合作；泡泡瑪特Q3收益近乎腰斬
SK海力士第三季度營業利潤和營收再創歷史新高，追加60萬億韓元股東回報計劃
港股概念追蹤 | PCB產業鏈迎來業績兑現期 兩家企業三季度淨利暴漲超10倍(附概念股)
衝刺人類史上最大IPO！Anthropic營收五季狂飆30倍，數千億美元算力盛宴開啟，誰在悶聲賺大錢？
美股前瞻 | 伊朗釋放和平信號！期指轉漲油價回落；SK海力士盤前升逾3%，將於盤后放榜！
從伊朗戰爭、政府腐敗到人工智能 美國中期選舉九大議題角力激烈
馬斯克警示新雲廠商：它們將迎來 「孔雀魚式消亡」
Anthropic公開遞交納斯達克IPO申請：上半年淨虧損807億美元
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
